/
PCVX
$58.07-$0.79 (-1.34%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.9B
149M shares
52-week range
$29.87 – $65.00
80% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$31.79
Vaxcyte, Inc. Common Stock
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
www.vaxcyte.com- Employees
- 507
- IPO / List date
- Jun 12, 2020
- HQ
- SAN CARLOS, CA
Held by traders on TradeandTell
No one on the platform currently holds PCVX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 54,734 | $3.2M |
| Bridgewater Associatesas of 2026-03-31 | 12,903 | $749.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PCVX yet.
